United States · Investor

Pivotal bioVenture Partners

Last cheque observed Jul 2026; 11 cheques on record.

Deploying nowNew fund $1.1M, Aug 2021VC firm

Series BSeries ASeries CLife SciencesTherapeuticsHealthcare

Deploying now
100%of best year1cheques in 12 months, 11 on record
Since the last cheque95days00hrs00min00sec
Median round$80MRounds led2 of 11Sole investor1 roundsMostly inUnited States, 70%
Pitch Pivotal bioVenture Partners

Pivotal bioVenture Partners highlights

  1. 01

    1 cheques in the last 12 months

  2. 02

    Mostly Series B and Series A: 82% of its rounds

  3. 03

    Sole investor in 1 rounds, median $54M

What they do

we are a life sciences venture capital firm investing in transformative therapeutic-focused healthcare companies across North America and Europe.From their own website
Type
VC firm
Cheque size
Not stated
Sectors
Life SciencesTherapeuticsHealthcare
Based in
San Francisco, United States
Cold pitches
Not stated

The record

Every round we can evidence, newest first11 appearances

  1. 2026

    1 round

  2. Jul
    Crystalys TherapeuticsSeries B · Frazier Life Sciences$130MWith 10 others
  3. 2025

    1 round

  4. Jun
    Mosanna TherapeuticsSeries A · CH · Silicon Canals$80MLed
  5. 2024

    1 round

  6. May
    Zenas BioPharmaSeries C · US · Tellus BioVentures$200MWith 14 others
  7. 2021

    1 round

  8. Aug
    Vigil NeuroscienceSeries B · US · Hatteras Venture Partners$90MWith 12 others
  9. 2019

    4 rounds

  10. Apr
    Inozyme PharmaSeries A · US · FinSMEs$67MWith 8 others
  11. Apr
    Fusion PharamaceuticalsSeries B · CA · FinSMEs$105MWith 11 others
  12. Mar
    Karuna TherapeuticsSeries B · US · FinSMEs$68MWith 8 others
  13. Feb
    Bolt BiotherapeuticsSeries B · US · Prnewswire$54MLed
  14. 2018

    1 round

  15. Jun
    SutroSeries E · US · FinSMEs$85MWith 17 others
  16. 2017

    2 rounds

  17. Sept
    Entasis TherapeuticsSeries B · US · FinSMEs$32MWith 2 others
  18. May
    Iterum TherapeuticsSeries B · IE · FinSMEs$65MWith 3 others

An announcement gives the size of the round, not the size of this investor's cheque: the only rounds that imply a cheque are those where they were the sole named investor.

The team

Named by the firm itself, on a filing, its Form ADV or its company registration7 named

BKBrian Kin Kwok TseOfficeriForm ADV
KHKin Ho KwokDirector of general partner of general partneriFiling they signed
MLMichael Lawrence TraversCorporate Counsel and Chief Operating OfficeriForm ADV
PTPeter Tuxen BisgaardDirector of the sole member of the General PartneriFiling they signed
RTRichard Tuxen ColesDirector of the sole member of the General PartneriFiling they signed
RLRobert Lorne HopfnerOfficeriForm ADV
VSVincent Sai Sing Tuxen CheungDirector of the sole member of the General PartneriFiling they signed

We also hold 18 people at this firm from the lists this database was built from: a weaker source than the filings, since a list does not say when a title ended. Login to see them.

What the register says

From the firm's own filings with the SEC, which it must file accurately by law

$586Mgross assets of its fundsOct 2026
Exemptreporting adviserventure or small private funds
Legal name
Pivotal Bioventure Partners Investment Advisor LLC
SEC number
CRD 287988

What they claim to have backed

From their own portfolio page (on their website)

0 of 1 we have independently watched raise

22fillmore

Weaker than a round we watched, stronger than a list somebody sold us. A firm is far less willing to put a company on its own site that it never funded.

Who they invest alongside

The investors most often in the same rounds as Pivotal bioVenture Partners. A count of rooms they were both in, not a relationship either has claimed.

Recently backed

The latest companies Pivotal bioVenture Partners put money into.

Quick answers about Pivotal bioVenture Partners

What does Pivotal bioVenture Partners invest in?

Pivotal bioVenture Partners invests most often at Series B and Series A (82% of the rounds on record), in sectors such as Life Sciences, Therapeutics and Healthcare.

How active is Pivotal bioVenture Partners?

11 investments on record, 1 of them in the last 12 months, and it led 2. The most recent was in Jul 2026.

What has Pivotal bioVenture Partners invested in recently?

Its most recent investments on record: Crystalys Therapeutics (Series B, Jul 2026), Mosanna Therapeutics (Series A, Jun 2025) and Zenas BioPharma (Series C, May 2024).

How big are Pivotal bioVenture Partners's cheques?

The median round it joins is $80M.

Does Pivotal bioVenture Partners lead rounds?

Yes: it led 2 of its 11 investments on record (18%).

Where does Pivotal bioVenture Partners invest?

Most of the companies it backs are in the United States (70%), Switzerland (10%) and Canada (10%).

Is Pivotal bioVenture Partners investing now?

Yes: it is actively investing, with 1 investments in the last 12 months.

Who does Pivotal bioVenture Partners invest alongside?

Most often Longitude Capital (3 rounds together), Cormorant Asset Management (2 rounds together) and Eventide (2 rounds together).

Raising now?

Find the investors who back rounds like yours, and keep every conversation on one fundraising board.

Built from the rounds we watched, its filings and its own website, refreshed every night. How we count · Report a correction · Is this your firm? Claim it